Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Texas Heart Institute designates this educational activity for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Estimated Study Time
The estimated time to complete this activity, including review of the materials and completion of the course assessment is 2 hours and 25 minutes.
If you previously completed and received credit for the live CME-sponsored symposium entitled, Heart Failure: Surgical and Medical Breakthrough in Current Practice on March 28, 2009, please note that you will not receive credit for completing this activity. Participants who take part in an identical activity, even in order to validate learning or to clarify specific topics, cannot claim, nor will the Texas Heart Institute award, duplicate credit for the activity.
Term of Approval
May 26, 2009 through May 26, 2012. Continuation of CME credit from May 26, 2012 depends upon a thorough review of the content for currency and accuracy.
In May 2009, this continuing medical education activity was reviewed for currency and accuracy of content by Patrick J. Hogan, MD, FACC, Director Learning Resource Center and Co-Chairman, Medical Education Committee, Texas Heart Institute, Houston, TX.
Disclosure of Relationships
It is the intent of the Texas Heart Institute to ensure that its educational mission and its continuing medical activities in particular, should not be influenced by the special interests of individuals associated with its program.
In accordance with the guidelines of the Accreditation Council for Continuing Medical Education, faculty members have disclosed their relationships, either with one or more of the manufacturers of commercial products discussed, or with one or more of the corporate organizations offering educational grants for the live continuing medical education activity.
J. Timothy Baldwin, PhD does not have any disclosures relevant to this program.
Reynolds M. Delgado III, MD (Program Director) discloses the following, relevant to this program: Consultant/Honoraria: Boston Scientific Corporation; Speaker's Bureau: GlaxoSmithKline.
O. H. Frazier, MD does not have any disclosures relevant to this program.
Douglas L. Mann, MD discloses the following, relevant to this program: Grant/Research Support: National Institutes of Health; Consultant: Acorn Cardiovascular, Inc. and Medtronic, Inc.; Scientific Advisory Board: ARMGO Pharma, Inc., Lpath Inc., Nile Pharmaceuticals, and Cardiokine, Inc.
James T. Willerson, MD does not have any disclosures relevant to this program.
James B. Young, MD does not have any disclosures relevant to this program.
In addition, peer reviewer, Patrick J. Hogan, MD has nothing to disclose relevant to this program.